Kodiak Sciences (NASDAQ:KOD) Stock Price Up 5.2% After Insider Buying Activity

Key Points

• Kodiak Sciences shares rose 5.2% to about $99.70 after insider Baker Bros. Advisors purchased roughly 1.94 million shares for approximately $157 million, significantly increasing its already substantial ownership.
• Analyst sentiment is generally positive, with six Buy ratings and a consensus “Moderate Buy” rating; price targets range from $96 to $145, with an average target of $100.43.
• The company’s prospects are supported by positive Phase 3 retinal-disease data and plans to advance Zenkuda toward a BLA filing, though Kodiak remains unprofitable, cash-burning and exposed to dilution and volatility risks.

Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) traded up 5.2% during mid-day trading on Thursday following insider buying activity. The company traded as high as $104.00 and last traded at $99.6990. 974,916 shares were traded during mid-day trading, a decline of 11% from the average session volume of 1,089,432 shares. The stock had previously closed at $94.80.

Specifically, Director Bros. Advisors Lp Baker acquired 807,840 shares of Kodiak Sciences stock in a transaction dated Monday, September 28th. The shares were purchased at an average cost of $72.57 per share, for a total transaction of $58,624,948.80. Following the transaction, the director owned 19,121,134 shares of the company's stock, valued at $1,387,620,694.38. This trade represents a 4.41% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 418,323 shares of the firm's stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average cost of $83.58 per share, for a total transaction of $34,963,436.34. Following the completion of the acquisition, the director owned 19,515,907 shares in the company, valued at $1,631,139,507.06. This represents a 2.19% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In other news, Director Bros. Advisors Lp Baker bought 33,726 shares of the business's stock in a transaction on Tuesday, September 29th. The stock was acquired at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the completion of the purchase, the director directly owned 20,191,214 shares in the company, valued at $1,717,262,750.70. This represents a 0.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Analyst Ratings Changes

KOD has been the topic of several research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Kodiak Sciences in a research note on Friday, July 10th. Wall Street Zen cut shares of Kodiak Sciences from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 26th. HC Wainwright increased their target price on shares of Kodiak Sciences from $58.00 to $96.00 and gave the company a "buy" rating in a report on Monday. Jefferies Financial Group reiterated a "buy" rating and issued a $112.00 target price on shares of Kodiak Sciences in a research report on Monday. Finally, Lifesci Capital upped their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an "outperform" rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Kodiak Sciences has a consensus rating of "Moderate Buy" and an average price target of $100.43.

Kodiak Sciences News Roundup

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Strong clinical results remain the primary catalyst. Phase 3 DAYBREAK data reportedly showed Zenkuda and KSI-501 meeting key endpoints against Eylea in wet age-related macular degeneration. Kodiak is advancing Zenkuda toward a BLA filing, strengthening the potential commercial opportunity in the retinal-drug market. Positive wet AMD data article
• Positive Sentiment: Analyst support and trading activity are increasing. HC Wainwright maintained a Buy rating and raised its price target to $96, while lifting its FY2029 EPS forecast to $1.76 from $0.18 and its FY2030 estimate to $5.81 from $3.04. The analyst also expects Kodiak to move from losses toward profitability in later years. Unusually high volume following the analyst upgrade indicates strong investor attention. Analyst upgrade and trading volume article
• Positive Sentiment: Insider buying provides an additional confidence signal. Director Bros. Advisors LP Baker reported purchases totaling approximately 1.94 million shares for about $157 million on September 28–29, materially increasing an already large ownership position. SEC insider purchase filing
• Neutral Sentiment: Analyst estimates were mixed in the near term. HC Wainwright slightly increased its projected FY2028 loss but reduced its FY2027 loss estimate only modestly, while significantly improving forecasts for FY2029 and FY2030.
• Negative Sentiment: Risks are elevated after the sharp run-up. Kodiak has no current revenue, remains cash-burning and may need to issue shares, creating dilution risk. Heavy put-option buying signals that some traders are hedging against volatility or a pullback. Kodiak valuation and financing risks article

Kodiak Sciences Price Performance

The stock has a market cap of $6.35 billion, a PE ratio of -24.15 and a beta of 2.18. The business has a 50 day moving average price of $41.32 and a two-hundred day moving average price of $38.77.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, sell-side analysts forecast that Kodiak Sciences Inc. will post -3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kodiak Sciences

Hedge funds have recently modified their holdings of the company. Engineers Gate Manager LP raised its stake in shares of Kodiak Sciences by 145.8% during the second quarter. Engineers Gate Manager LP now owns 29,537 shares of the company's stock valued at $1,151,000 after acquiring an additional 17,520 shares during the last quarter. Squarepoint Ops LLC grew its stake in shares of Kodiak Sciences by 112.6% in the second quarter. Squarepoint Ops LLC now owns 151,098 shares of the company's stock worth $5,887,000 after purchasing an additional 80,042 shares during the last quarter. Arizona State Retirement System increased its holdings in Kodiak Sciences by 6.9% during the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company's stock valued at $332,000 after purchasing an additional 554 shares during the period. Hsbc Holdings PLC purchased a new position in Kodiak Sciences during the 2nd quarter valued at about $232,000. Finally, Wellington Management Group LLP raised its position in Kodiak Sciences by 81.9% during the 2nd quarter. Wellington Management Group LLP now owns 793,613 shares of the company's stock valued at $30,919,000 after purchasing an additional 357,284 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

About Kodiak Sciences

Kodiak Sciences Inc NASDAQ: KOD is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company's research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.